TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Ultrasound-guided Paravertebral Block Versus Intravenous Tramadol in Percutaneous Nephrolithotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 53 patients scheduled for percutaneous nephrolithotomy (PNL),~* 18-70 years of age,~* weight between 50-100 kg,~* American Society of Anesthesiologists (ASA) classification I-II were included~Exclusion Criteria:~* The exclusion criteria were refusals by patients,~* coagulation abnormalities,~* patients with spinal deformity,~* cutaneous infection at the injection site and~* a known allergy to drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group Paravertebral Block (Type: ACTIVE_COMPARATOR): With ultrasound guidance at T10 to L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. 5 mL bupivacaine 0.5% was injected in each dermatome level.
- Group tramadol (Type: PLACEBO_COMPARATOR): Patients in group T were given a loading dose of tramadol of 1 mgkg-1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Controlled Study on Short-term Psychotherapy After Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted to San Filippo Neri Hospital for AMI and treated with primary or urgent PCI.~* Primary PTCA is performed up to 12 hours after the beginning of chest pain in cases of STEMI, while patients with NSTEMI are enrolled if urgent PTCA is being performed within 48 hours of the onset of chest pain.~* Only patients in whom complete revascularization is achieved are being enrolled in the study.~Exclusion Criteria:~* Patients with psychiatric disorders or disability, cognitive impairment, or other life-threatening conditions are being excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Psychotherapy (Type: EXPERIMENTAL): Psychotherapy and medical therapy
- Control (Type: ACTIVE_COMPARATOR): Optimal medical therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 and \<70 years of age at initiation of treatment~* Body weight between 50 kg and 125 kg at baseline~* Chronic hepatitis C, genotype 1~* Chronic liver disease consistent with HCV infection~* Compensated liver disease (Child-Pugh Grade A)~Exclusion Criteria:~* Pregnant or lactating women, and male partners of pregnant women~* Chronic hepatitis C, genotype 2, 3, 4, 5 or 6~* Previous treatment with interferon or ribavirin~* Positive for hepatitis A, hepatitis B or HIV infection~* History or evidence of a medical condition associated with liver disease other than chronic hepatitis C~* Decompensated liver disease and/or liver disease Child-Pugh classification \>6~* Hepatocellular carcinoma~* History or evidence of esophageal bleeding~* Hemoglobinopathy, or any other cause for possible hemolysis~* Hb \<11 g/dL in women, \<12 g/L in males

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Peginterferon Alfa-2a Plus Ribavirin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone in Pain Control After Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-III~* Age 18-80 years old~* Scheduled for elective primary unilateral total knee replacement~* Chinese patients~* Able to speak and understand Cantonese~* Able to provide informed oral and written consent~Exclusion Criteria:~* Revision total knee replacement~* Single stage bilateral total knee replacement~* Known allergy to opioids, local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDS) including COX-2 inhibitors~* History of chronic pain other than chronic knee pain~* History of insulin dependent diabetic mellitus, but not diabetic mellitus on oral hyperglycaemic agents~* History of hepatitis B or C carrier~* History of peptic ulcer~* Hx of tuberculosis~* History of immunosuppression~* Daily use of glucocorticoids~* Daily use of strong opioids (morphine, fentanyl, hydromorphone, ketobemidone, methadone, nicomorphine, oxycodone, or meperidine)~* History of severe heart disease (NYHA 2)~* Alcohol or drug abuse~* Impaired renal function, defined as preoperative serum creatinine level over 120micromol/L~* Pre-existing neurological or muscular disorders~* Psychiatric illness or neurologic or psychiatric diseases potentially influencing pain perception~* Impaired or retarded mental state~* Difficulties in using patient controlled analgesia (PCA)~* Pregnancy~* Local infection~* On immunosuppresants~* Patient refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group D1 (Type: ACTIVE_COMPARATOR): Patients from group D will be given a bolus injection of 2 ml saline with 2 ml dexamethasone (4mg/ml) before skin incision.
- Group D2 (Type: EXPERIMENTAL): 4ml bolus injection of dexamethasone (4mg/ml) will be given intravenously prior to incision.
- Group C (Type: PLACEBO_COMPARATOR): 4ml bolus injection of 0.9% saline will be given intravenously prior to incision

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants having completed the VIPV-07 trial~2. Healthy assessed from medical history and physical examination~3. Parent(s)/guardian(s), according to the local legal requirements, have been properly informed about the trial and have signed the informed consent form~4. Parent(s)/guardian(s), according to the local legal requirements, have granted access to the infant's trial related medical records~5. Parent(s)/guardian(s), according to the local legal requirements, are likely to comply with trial procedures~Exclusion Criteria:~1. Previously vaccinated with OPV~2. Previously vaccinated with IPV outside the VIPV-07 trial~3. Known or suspected immunodeficiency (e.g. leukaemia or lymphoma) or family history of congenital or hereditary immunodeficiency. HIV infection is not an exclusion criterion~4. Severe uncontrolled chronic disease (e.g. neurologic, pulmonary, gastrointestinal, hepatic, renal or endocrine)~5. Known or suspected allergy to vaccine constituents (e.g. hypersensitivity to formaldehyde, aluminium or 2-phenoxyethanol)~6. Previous Yellow Fever vaccination~7. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections or blood sampling~8. In treatment with systemic corticosteroids given p.o., i.v., i.m. ≤ 1 month prior to inclusion or during the trial. Subjects administered corticosteroid topically or by asthma inhalators are eligible for inclusion~9. Treatment with a product, which is likely to modify the immune response (e.g blood products and immunoglobulins) ≤ 3 months prior to inclusion or planned during the trial period~10. Participating in another interventional clinical trial~11. Not suitable for inclusion in the opinion of the investigator

- Gender: ALL
- Minimum Age: 15 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- IPV-Al SSI (Type: EXPERIMENTAL): Single arm trial. All subjects will receive the IPV-Al SSI as booster vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ≥ 40 years of age~* Established clinical history of COPD by ATS/ERS definition~* Former or current smoker \> 10 pack years~* Evidence of dyspnea~Exclusion Criteria:~* Has a respiratory disorder other than COPD~* Cancer not in complete clinical remission~* Clinically significant cardiovascular, neurological, psychiatric, renal, gastro-intestinal, immunological, endocrine, or hematological abnormalities that are uncontrolled

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FSC (Type: EXPERIMENTAL): Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day
- SAL (Type: EXPERIMENTAL): Salmeterol 50mcg DISKUS twice a day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo DISKUS twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An fMRI Study of Self-regulation in Adolescents With Bulimia Nervosa

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Current or prior DSM IV diagnosis of Bulimia Nervosa or Sub-threshold Bulimia Nervosa (those who meet all DSM-IV criteria for BN, but engage in subjective binge-eating episodes and binge/purge at a frequency of at least once per week for 3 months, whereas meeting full DSM-IV criteria for BN requires binge eating and purging twice per week for 3 months)~* Major Depression~* For control adolescents, no current or past history of an eating disorder~Exclusion Criteria:~* Ferromagnetic implants (e.g., pacemaker)~* Metal braces or retainers~* IQ less than 80~* Any other current major Axis I disorder, other than major depressive disorder (MDD)~* History of concussion, seizure disorder, or other neurological illness~* Claustrophobia~* Pregnant

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Adolescents with Bulimia Nervosa or subclinical BN (Type: None): Adolescents with Bulimia Nervosa or subclinical Bulimia Nervosa
- Healthy control adolescents (Type: None): Healthy control adolescents

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects are required to be 18 years of age or older and have a presumptive diagnosis of SHS post-stroke with a minimum visual analog scale of 40mm (greater than 40mm is considered moderate pain).~Exclusion Criteria:~* Subjects will be excluded from the study if they have significant cognitive impairment (mini-mental state examination \<23) and language deficits (difficulty cooperating due to aphasia) as this may affect their response to the outcome measures. Subjects with uncontrolled hypertension (\>180/110), septicemia, and brachial plexus injuries will be excluded. Patients who are blind and deaf will also be excluded, as they will be unable to adequately complete the post-procedure survey and VAS. Patients on anticoagulation medications will also be excluded on a case-by-case basis and medications will be held prior to injection if required for safety. Patients with INR \>1.5 will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open label treatment (Type: EXPERIMENTAL): These patients will receive suprascapular and median nerve blocks for shoulder hand syndrome. Investigators will assess the tolerability of his procedure using pre-defined criteria (outlined elsewhere).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, \>/= 18 years of age~* Stage IV or recurrent non-small cell lung cancer (NSCLC)~* Presence of mutation(s) in exon 18 through exon 21 of epidermal growth factor receptor (EGFR), (except T790M single mutation only)~* Measurable disease (at least one lesion \>= 10 mm in longest diameter)~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Adequate hematological, renal and liver function~Exclusion Criteria:~* Patients with T790M single mutation only~* Prior exposure to agents directed at the human epidermal receptor (HER) axis, e.g. erlotinib, gefitinib, cetuximab, trastuzumab~* Prior chemotherapy or systemic anti-cancer therapy for advanced NSCLC disease~* Symptomatic or uncontrolled central nervous system (CNS) metastases~* Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal or squamous cell carcinoma of the skin, or surgically treated localized prostate cancer, or surgically treated ductal cell carcinoma in situ of the breast~* Any significant ophthalmologic abnormality~* Pre-existing parenchymal lung disease such as pulmonary fibrosis~* Use of coumarins (for anti-coagulation therapy the use of low molecular weight heparin is recommended instead)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Erlotinib 150 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed prostate cancer (all stages) for whom androgen deprivation therapy is indicated (except when indicated in a neoadjuvant/adjuvant therapy)~* Asymptomatic from prostate cancer~* Non-castrate level of testosterone (≥ 8 nmol/L (230 ng/dL)) at screening~* PSA ≥ 2 ng/mL at screening~Exclusion Criteria:~Has previously or is currently receiving:~* Hormonal therapy with intent to treat prostate cancer~* Systemic glucocorticoids~* Chemotherapy with the intent to treat prostate cancer~* Opiate analgesics for pain from prostate cancer~* Radiation therapy for treatment of the primary tumor or metastases~* Has history of known or suspected brain or skull metastases or leptomeningeal disease~* Has history of seizure including febrile seizure or any condition that may predispose to seizure or history of loss of consciousness or transient ischemic attack~* Clinically significant cardiovascular disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzalutamide (Type: EXPERIMENTAL): Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mean seated blood pressure greater than or equal to 140/90 mmHg under circumstances in pre-treatment with olmesartan medoxomil~* Mean 24-hour blood pressure evaluated by ambulatory blood pressure monitoring greater than or equal to 135/80 mmHg under circumstances in pre-treatment with olmesartan medoxomil~Exclusion Criteria:~* Patients with secondary hypertension~* Any serious disorder which may limit the ability to evaluate the efficacy or safety of the test drugs

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): olmesartan medoxomil tablets and a CCB tablet (of the dihydropyridine class), once daily for 8 weeks
- 2 (Type: EXPERIMENTAL): olmesartan medoxomil and a diuretic tablet (of the thiazide class)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Serologically-confirmed HIV and HBV infection~* Willingness to participate in a clinical trial~* No previous or current use of antiretroviral regimen~* Clinical conditions stable~* Blood creatinine less than 3 times the upper limit of normal values. HBV DNA\>1000copies/ml, Tbil\<34umol/L,ALT\<400U/L~* With clinical indications for HAART~Exclusion Criteria:~* Patient refuses to sign the consent to participate~* Unwillingness to adhere to visit schedule or maintain adherence with medications~* Illnesses so serve as to likely require hospitalization~* With other conditions that not suitable to be enrolled will be subject to medical review

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- TDF/3TC/EFV Treatment HIV/HBV Co-infection (Type: EXPERIMENTAL): TDF+3TC+EFV treatment regimen in Adults with HIV/HBV Coinfection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Somatropin Treatment to Final Height in Turner Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* girl with Turner syndrome~* prepubertal, Tanner stage I breast~* height velocity less than 6 cm/year and height less than or equal to the tenth percentile for sex and age in general population~* at least 6 months (preferably 12 months) of accurate height measurements available for calculation of pre-study height velocity~* if thyroxine deficient, to have received replacement therapy, and for six months prior to enrollment have had normal thyroid function tests~Exclusion Criteria:~* prior treatment with growth hormone~* presence of a Y component in karyotype with gonads in situ~* diabetes mellitus

- Gender: FEMALE
- Minimum Age: 7 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Control arm; untreated with Humatrope. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).
- Humatrope (Type: EXPERIMENTAL): Humatrope (0.05 mg/kg/dose) by subcutaneous injection 6 times per week. Ethinyl estradiol (escalating doses to 20 mcg daily) after age 13, and medroxyprogesterone acetate (10 mg tablets ten days monthly) after age 15. Subject continues until Core study completion criteria are met (protocol final height).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete